Iyo abantu bagereranije ibisekuru bizaza bivura metabolike, izina rimwe rigenda rigaragara ni retatrutide. Inyungu muri iyi molekile yakuze vuba kuko yerekana uburyo bwagutse bwa farumasi kuruta tirzepatide, yibasira reseptor eshatu aho kuba ebyiri. Muri icyo gihe, tirzepatide isanzwe ifite umwanya ukomeye ku isi: iremewe na FDA, iraboneka mu bucuruzi, kandi ishyigikiwe n’ibisubizo by’amavuriro mu bwoko bwa metabolism yo mu bwoko bwa 2, umubyibuho ukabije, ndetse no gusinzira bikabije ku bantu bakuru bafite umubyibuho ukabije. Ibyo bikora igereranya rikomeye. Kuruhande rumwe hashyizweho agonisti ebyiri ikoreshwa neza uyumunsi; kurundi ni agoniste nshyashya ya agonist benshi babikurikiranira hafi babona ko ari intambwe ikurikira mu buvuzi bwa metabolike. Niba ikibazo aricyo kiyobyabwenge gishimishije muburyo bwo guhanga udushya, retatrutide ikunze kugaragara cyane. Niba ikibazo aricyo kiyobyabwenge kiboneka muri iki gihe, tirzepatide iyobora neza. Urufunguzo ni ugusobanukirwa aho batandukaniye muburyo, imikorere, imiterere yubuyobozi, imiterere yumutekano, hamwe nubushobozi bwigihe kirekire.
Tirzepatid ni peptide inshuro imwe mucyumweru yatewe inshinge yakozwe na Lilly ikora nka agonisti ebyiri ya reseptor ya GIP na GLP-1. Muri Amerika, tirzepatide yemerewe nka Mounjaro kugenzura glycemic yo mu bwoko bwa metabolism yo mu bwoko bwa 2 ndetse na Zepbound yo gucunga ibiro bidakira ku bantu bakuru bafite umubyibuho ukabije, cyangwa umubyibuho ukabije nibura ufite ikibazo kimwe kijyanye n'uburemere. Zepbound nayo yemerewe na FDA kubitotsi bitarenze urugero-bikabije kubuza gusinzira apnea kubantu bakuze bafite umubyibuho ukabije. Iyo miterere igenga tirzepatide inyungu nyamukuru kumasoko yiki gihe.
Retatrutid nayo ni peptide ya rimwe mu cyumweru iterwa na Lilly, ariko igenda iyindi ntambwe. Aho gukora kuri reseptor ebyiri, ni agoniste inshuro eshatu yibasira GIP, GLP-1, na glucagon. Lilly abisobanura nka molekile yiperereza, kandi guhera muri Werurwe-Mata 2026 ikomeza kuba mu mavuriro aho gukoreshwa mu bucuruzi rusange. Isosiyete ivuga neza ko retatrutide itemewe n’ikigo icyo ari cyo cyose gishinzwe kugenzura kandi ko byemewe n'amategeko gusa ku bitabiriye ibizamini byatewe inkunga na Lilly.
Iyo miterere yiperereza ningirakamaro, ariko ntigabanya impamvu molekile ikurura abantu cyane. Retatrutid ntabwo irimo kwigwa gusa mubyibushye gusa no muburyo bwa 2 metabolisme, ahubwo no mubice byinshi byumutima wa kardiometabolike, harimo indwara zifata umutima nimiyoboro y'amaraso, indwara ziterwa na metabolike y'umwijima, ububabare budakira bw'umugongo bukabije, hamwe n'ububabare bwo mu ivi osteoarthritis bujyanye n'umubyibuho ukabije cyangwa umubyibuho ukabije. Ubu bugari bwerekana ko abashakashatsi babona retatrutide atari umukandida ugabanya ibiro gusa, ahubwo ko ari urubuga rwagutse.
Tirzepatid nka agoniste ebyiri
Tirzepatid ikora GIP na GLP-1. Iki gikorwa cyombi gishyigikira kunoza imisemburo ya insuline, glucose yamaraso, gutinda gusohora gastrica, kugabanya ubushake bwo kurya, no kugabanya ibiro bifite akamaro. Ku barwayi benshi, ubwo bufatanye bumaze gukora neza. Nimpamvu imwe tirzepatide yabaye izina rikomeye mubyibushye no kwita kuri metabolism.
Retatrutid nkinshuro eshatu agonist
Retatrutid ikora GIP, GLP-1, na glucagon reseptor. Igice cya glucagon nicyo gishimisha cyane. Mugihe glucagon ikunze kuba ifitanye isano no kuzamura glucose yamaraso, muburyo bukwiye bwa farumasi irashobora kandi gushyigikira kongera ingufu zikoreshwa ningufu za metabolisme. Iyo nzira yongeyeho nimpamvu nyamukuru ituma retatrutide ikunze kuganirwaho nkibishobora gukomera kuruta tirzepatide duhereye kubiro.
Kuki abahanga benshi bareba retatrutide neza
Urebye mubumenyi, retatrutide yerekana igishushanyo mbonera cyagutse. Tirzepatid yari imaze gutera intambwe ikomeye ituruka ku biyobyabwenge byinzira imwe; retatrutide irashobora kuba igerageza gukurikira kwagura ingaruka zo kuvura. Ibyo ntabwo bihita bituma 'byiza ' muri buri murwayi cyangwa buri kibazo cyakoreshejwe, ariko gisobanura impamvu gikunze gufatwa nkumukandida udushya. Iyi ni umwanzuro ushingiye ku itandukaniro riri hagati ya reseptor ebyiri na gatatu hamwe nibimenyetso bikomeye byo kugabanya ibiro bigaragara kugeza ubu.
Tirzepatid yamaze gutanga umusaruro ushimishije. Muri SURMOUNT-1, abantu bakuru bafata Zepbound 15 mg batakaje impuzandengo ya 20.9% yuburemere bwumubiri mugihe cyibyumweru 72, naho mubushakashatsi bwakozwe na SURMOUNT-5, tirzepatide yerekanye 20.2% kugabanya ibiro byibuze mubyumweru 72 na 13.7% hamwe na semaglutide. Ibyo nibisubizo byingenzi kurwego urwo arirwo rwose.
Retatrutid, ariko, niho ikiganiro kiba gishimishije cyane. Mu cyiciro cya 2 cya Lilly ibisubizo by’umubyibuho ukabije byatangajwe mu 2023, retatrutide yageze kuri 24.2% bivuze kugabanya ibiro mu byumweru 48 nkumwanya wa kabiri. Vuba aha, Lilly yatangaje icyiciro cya 3 cyubwoko bwa 2 metabolism yerekana ko A1C yagabanutseho 1,7% kugeza kuri 2.0% mugihe cyibyumweru 40 naho kugabanya ibiro byumubiri bigera kuri 16.8% kuri 12 mg. Lilly yatangaje kandi mu mpera za 2025 TRIUMPH-4 bivamo umubyibuho ukabije / umubyibuho ukabije hamwe na osteoarthritis yo mu ivi, aho retatrutide 12 mg yatanze 28.7% kugabanya ibiro by’umubiri ku kigereranyo cya efficacy, nubwo iyo miterere yihariye itandukanye cyane no kugereranya umubyibuho ukabije.
Icyiciro |
Tirzepatid |
Retatrutid |
Ijambo ryibanze ryingenzi |
Gereranya muriyi ngingo |
Hejuru, nkibigaragara |
Intego za reseptor |
GIP + GLP-1 |
GIP + GLP-1 + glucagon |
Imiterere y'ubu |
FDA yemewe kubwoko bwa 2 metabolism; byemewe nka Zepbound kubyibushye / kubyibuha birenze na OSA mubantu bakuru bafite umubyibuho ukabije |
Iperereza gusa |
Kwinjira muri iki gihe |
Gukoresha imiti yerekana ibimenyetso byemewe |
Igeragezwa rya Clinical gusa |
Umwirondoro wo kugabanya ibiro |
Birakomeye kandi byemewe mubucuruzi |
Ibimenyetso bikomeye birashobora kugeza ubu, ariko biracyatera imbere |
Umwirondoro wo guhanga udushya |
Iterambere ryinshi hejuru ya GLP-1-yonyine |
Akenshi urebwa nkintambwe izakurikiraho |
Ingaruka zo gukabya |
Hasi, kuko byemewe |
Hejuru, kuko ibimenyetso biracyagaragara |
Muri rusange imyumvire |
Guhitamo kwiza muri iki gihe |
Umukandida ushimishije cyane |
Imbonerahamwe ituma ingingo nkuru yoroshye kubyumva: tirzepatide nuburyo bukomeye bwumunsi, mugihe retatrutide ishobora kuba amahitamo akomeye-ahazaza.
Kuberako tirzepatide yemewe, ururimi rwumutekano rurakuze kandi rwanditse neza. Ibisobanuro byibicuruzwa byerekana gastrointestinal reaction reaction nka isesemi, impiswi, kuruka, kuribwa mu nda, kubabara munda, na dyspepsia mubibazo bisanzwe. Agasanduku ko kuburira no kurwanya imvugo nayo irahari muri label ya Amerika.
Retatrutid ni kare mubuzima bwayo, bityo ishusho yayo yo kwihanganira ntabwo yuzuye. Ibisubizo bya Lilly byavuzwe mu cyiciro cya 3 metabolism bivuga ko ibintu byakunze kugaragara ari gastrointestinal, harimo isesemi, impiswi, no kuruka, cyane cyane mugihe cyo kwiyongera kwa dose. Ibyo birahuye cyane nibyo abaganga babonye muburyo bwo kuvura bushingiye kuri incretin, ariko retatrutide iracyakeneye igihe kinini na datasets nini mbere yuko umwirondoro wuzuye usobanuka.
Molekile irashobora kugaragara nkimbaraga kandi iracyasaba kwitonda cyane. Ngiyo kuringaniza hano. Retatrutid irashobora kugaragara nkibyiringiro muburyo bwa mehaniki kandi amaherezo irashobora kwerekana ko ikora neza kubarwayi bamwe na bamwe, ariko tirzepatide kuri ubu ifite inyungu zumutekano usobanuwe neza hamwe na label.
Ku barwayi n’abaganga bafata ibyemezo uyumunsi , tirzepatide nigisubizo gifatika kuko cyemejwe, cyateganijwe, kandi gishyigikiwe na label yemewe. Nuburyo bwo gukoresha-isi ikoreshwa ubu.
Kubashakashatsi, abakurikirana imiyoboro, hamwe nabasomyi bashishikajwe n’ubuvuzi bwa metabolike bugana, retatrutide irashobora kuba molekile ishimishije cyane kubera ibintu bitatu:
1. Uburyo bwagutse binyuze muri agonism eshatu.
2. Ibimenyetso bikomeye cyane byo kugabanya ibiro mugice cya 2 no gutera inkunga icyiciro cya 3.
3.Iterambere ryagutse ryiterambere murwego rwumubyibuho ukabije hamwe na cardiometabolike.
Nubwo rero bidakwiye kuvuga ko retatrutide isanzwe ivurwa neza kwisi, birakwiye kuvuga ko retatrutide ari umukandida abantu benshi bareba neza ejo hazaza. Uku gushushanya gufata amasezerano yayo hamwe nimbibi zayo.
Hariho urutonde rwibigeragezo byemewe kubushakashatsi bugereranya retatrutide na tirzepatide kubantu bakuze bafite umubyibuho ukabije, byerekana uburyo iri gereranya ryabaye ishingiro. Gahunda yagutse ya Lilly nayo irakomeza binyuze mubushakashatsi bwinshi bwa TRIUMPH na TRANSCEND. Muyandi magambo, ikibazo ntikikiri niba retatrutide ari ngombwa; ni ukumenya niba amakuru yayo azaza azakomera bihagije kugirango yemeze ihinduka rinini ryo kuvura.
Niba ibisubizo bikomeje bikomeza gushimangira kugabanuka gukomeye hamwe ninyungu nini za metabolike, retatrutide amaherezo ishobora kuba imwe mubyingenzi byingenzi bizaza bivura umubyibuho ukabije mu iterambere.
Iyo ugereranije tirzepatide na retatrutide, umwanzuro mwiza ntabwo aruko umuntu yamaze 'gutsinda, ' ahubwo ko bafite imyanya itandukanye murwego rwo kuvura. Tirzepatid niyo nzira yashizweho, ishyigikiwe no kwemerwa, kuboneka, no gukoresha amavuriro menshi. Retatrutid numukandida ureba imbere, ashyigikiwe nuburyo bwagutse butatu-agoniste hamwe namakuru arushijeho gutangaza yerekana ko ashobora gutera imbere murwego niba ibisubizo bizaza bikomeje. Dukurikije uko tubibona, niyo mpamvu rwose retatrutide ikwiye kwitabwaho cyane.Birashobora gushishoza Cocer Peptides Co, Ltd. kubindi bisobanuro.
Yego. Tirzepatid yemerewe na FDA kubwoko bwa metabolisme yo mu bwoko bwa 2 nka Mounjaro no kubyibuha / umubyibuho ukabije na OSA kubantu bakuze bafite umubyibuho ukabije nka Zepbound, naho retatrutide ikomeje iperereza.
Kuberako yibasira ibintu bitatu byakira - GIP, GLP-1, na glucagon - aho kuba bibiri, bishobora gutanga ingaruka nini za metabolike kandi birashoboka cyane ko gutakaza ibiro.
Ibimenyetso byo hambere no hagati birakomeye cyane, harimo icyiciro cya 2 umubyibuho ukabije ugera kuri 24.2% bivuze kugabanya ibiro mugihe cyibyumweru 48 hanyuma nyuma yo kugerageza kugeragezwa hamwe n’imibare minini-igereranya n’imibare mubantu bamwe, ariko kugereranya iburanisha biracyakeneye kwitonda.
Oya. Lilly avuga ko retatrutide iboneka byemewe n'amategeko binyuze mu bigeragezo byayo by’amavuriro, kandi FDA yihanangirije abaguzi kutagura ibicuruzwa bitemewe bigurishwa nk’imiti ikoreshwa na GLP-1.
